Adaptimmune Therapeutics PLC: Nasdaq/NYSE listing notice — Adaptimmune regains Nasdaq minimum bid price compliance; ADSs to remain listed

Adaptimmune Therapeutics PLC

Received Nasdaq letter on Feb 16, 2024 confirming compliance with Listing Rule 5450(a)(1).
Previously notified of non-compliance on Aug 31, 2023; ADSs closed below $1.00 for 30 consecutive days.
Closing bid price exceeded $1.00 for ten consecutive trading days through Feb 15, 2024.
Company now in full compliance with all Nasdaq listing standards; matter closed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adaptimmune Therapeutics PLC received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 16, 2024, Adaptimmune Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market. Consequently, the Company is now in compliance with all applicable listing standards, and it will continue to be listed on The Nasdaq Global Select Market. The Company was previously notified by Nasdaq on August 31, 2023 that it was not in compliance with the minimum bid price requir

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-24-001304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.